Navigation Links
Agendia Raises US $23 Million in Series E Financing
Date:9/22/2009

HUNTINGTON BEACH, California and AMSTERDAM, September 22 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the successful closing of a US $23 million series E investment. The financing round was led by an undisclosed family investment firm that provided approximately half of the funds. In addition, two independent entrepreneurs participated with an investment of US $1 million each, while the remaining capital was raised through Agendia's existing investor base.

"The success of this financing round was aided by MammaPrint(R)'s increasing U.S. demand, as well as growing reimbursement from private U.S. payors. The proceeds will be used to accelerate the commercialization of MammaPrint in the U.S. market," said Dr. Bernhard Sixt, President and Chief Executive Officer of Agendia.

"We are excited to be a part of Agendia's continued growth and to enable the company to bolster its strategic marketing and sales efforts as it brings MammaPrint to an ever increasing number of breast cancer patients," said Gertjan van der Baan, Board Member on behalf of van Herk Group, Agendia's largest investor.

Dr. Sixt will present at the UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 1 p.m. (ET) in Ballroom D at the Grand Hyatt in New York.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provid
'/>"/>

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
2. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
3. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
4. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
5. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
6. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
7. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
8. Agendia Appoints VP of Business Development
9. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
10. Agendia Appoints New Chief Financial Officer
11. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 20, 2015 Research and Markets ( ... "Top Technologies in HW_Technical Insights" report to their ... evaluated technology trends in the Health and Wellness sector ... to have an impact in the year 2015. The ... top 10 health and wellness technologies that are anticipated ...
(Date:5/20/2015)... , May 20, 2015  Select Medical ... the Federal Trade Commission granted early termination of ... Improvements Act of 1976, as amended, applicable to ... Acquisition Corporation, a joint venture that Select has ... As previously announced, MJ Acquisition Corporation ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 Agricultural firm ... anniversary of its acquisition of Tiger-Sul. Since the ... (Calgary Alberta, Canada) in May 2005, H.J. Baker has ... build it into a comprehensive portfolio of product offerings ... of H.J. Baker and the innovation of Tiger-Sul, transforming ...
(Date:5/20/2015)...  Cypher Genomics, Inc., a leading genome informatics ... to apply Cypher,s Coral TM technology to ... response to innovative medicines. The information generated from ... access to the right medicine at the right ... and potentially inform new companion diagnostics.  ...
Breaking Biology Technology:Top Technologies in the Health and Wellness Industry 2015 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... LLC.,today announced the addition of Mark Scherling to ... FCP as Program,Management Office and Siemens Practice Director., ... thought leadership,experience to FCP. Prior to joining FCP, ... at Catholic Healthcare West. Prior to that,responsibility, Mark ...
... Technologies GmbH,the leading developer of RAFT intervention therapeutics, ... trial of its lead RAFT modulator,TF002 in patients ... miltefosine, exerts its anti- inflammatory activity via RAFT,modulation. ... cells that,play a role in the complex physiological ...
... February 15, 2008 USC and Second Sight Medical Products ... announced today that they have completed enrollment of the first ... Argus II Retinal Prosthesis System. They also announced that enrollment ... Mexico. , We are pleased that Second Sight, along ...
Cached Biology Technology:FCP Welcomes Mark Scherling 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 3USC and second sight announce European clinical trial for Argus II retinal implant 2USC and second sight announce European clinical trial for Argus II retinal implant 3
(Date:5/14/2015)... DUBLIN , May 14, 2015 Research and ... addition of the "Fingerprint Sensors Market in Smart ... This report believes that 2014 was a watershed ... to Apple,s introduction of ,Apple Pay,. Apple gave fingerprint ... its mobile payment service. Fingerprint sensors are a must-have ...
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Fla. For years, pilots flying into combat have jammed ... turns out that moths can do it, too. A ... hawkmoths use sonic pulses from their genitals to respond to ... to jam the echolocation ability of their predators. ...
... the VTT Technical Research Centre of Finland, lignocellulosic biomass can ... price of less than one euro per litre. A new ... half the energy of wood raw materials to the end-product. ... commercial-scale production plant in Europe. VTT has assessed the ...
... 2000, researchers at the UCLA Center for Sleep Research ... disorder characterized by uncontrollable periods of deep sleep, had ... their brains than healthy people. The study was the ... disorder. Subsequent work by this group ...
Cached Biology News:UF researcher shows hawkmoths use ultrasound to combat bats 2UF researcher shows hawkmoths use ultrasound to combat bats 3Gasification method turns forest residues to biofuel with less than a euro per liter 2UCLA researchers find new clue to cause of human narcolepsy 2
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: